Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


The increasing potency of therapies that target the androgen receptor (AR) signalling axis has correlated with a rise in the proportion of patients with prostate cancer harbouring an adaptive phenotype, termed treatment-induced lineage crisis. This phenotype is characterized by features that include soft-tissue metastasis and/or resistance to standard anticancer therapies. Potent anticancer treatments might force cancer cells to evolve and develop alternative cell lineages that are resistant to primary therapies, a mechanism similar to the generation of multidrug- resistant microorganisms after continued antibiotic use. Herein, we assess the hypothesis that treatment-adapted phenotypes harbour reduced AR expression and/or activity, and acquire compensatory strategies for cell survival. We highlight the striking similarities between castration-resistant prostate cancer and triple-negative breast cancer, another poorly differentiated endocrine malignancy. Alternative treatment paradigms are needed to avoid therapy-induced resistance. Herein, we present a new clinical trial strategy designed to evaluate the potential of rapid drug cycling as an approach to delay the onset of resistance and treatment-induced lineage crisis in patients with metastatic castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)269-283
Number of pages15
JournalNature Reviews Clinical Oncology
Issue number5
StatePublished - 1 May 2017


Dive into the research topics of 'Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer'. Together they form a unique fingerprint.

Cite this